Predictive Lung Deposition Models for Safety and Efficacy of Orally Inhaled Drug Products Program.

by: Iola Bonggay

The United States Food and Drug Administration, otherwise referred to as the USFDA, an agency operating within the United States Department of Health and Human Services that is generally responsible for protecting and promoting public health through the regulation and supervision of food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs, vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting devices, veterinary products, and cosmetics.

The USFA has recently formed a collaboration with the National Institutes of Health to establish the Predictive Lung Deposition Models for Safety and Efficacy of Orally Inhaled Drug Products Program.

The primary goal of the program is to develop computational fluid dynamics (CFD) model of orally inhaled drug products that can account for drug product characteristics and physiological parameters on total and regional deposition in the lungs.

This is all in conjunction with the USFDA's objective of developing a CFD model that will be capable of of predicting highly localized deposition of pharmaceutically relevant polydisperse aerosols from metered dose inhalers (MDIs) and dry powder inhalers (DPIs).

In addition, the results that will be derived from this study will then be utilized to create a linked CFD-compartment model that can predict the effects of lung deposition on safety (systemic exposure) and efficacy (local delivery) for locally acting orally inhaled drugs.

  (continued...)

Predictive Lung Deposition Models for Safety and Efficacy of Orally Inhaled Drug Products Program.
  Page 2

About The Author Iola Bonggay is an editor of TopGovernmentGrants.com one the the most comprehensive Websites offering information on government grants and federal government programs. She also maintains Websites providing resources on environmental grants and grants for youth programs.

Additional Resources

category - Health Grants

Exploratory/Developmental Grants Program for Basic Cancer Research in Cancer Health Disparities
The National Institutes of Health has recently formed a partnership with the National Cancer Institute (NCI) in an effort to constitute the Exploratory/Developmental Grants Program for Basic Cancer Research in Cancer Health Disparities wherein both agencies intend to solicit grant application from various eligible researchers who are interested in conducing basic research studies regarding the biological causes and mechanisms of cancer health disparities.

---

Cancer Education Grants Program
The National Cancer Institute has developed the Cancer Education Grants Program wherein it seeks to financially support innovative educational efforts that would contribute to the reduction of cancer incidences, morbidity and mortality rates; as well as the improvement of the quality of life of surviving cancer patients.

---

2012 Tuberous Sclerosis Complex Clinical Trial Award Program
In line with this mission, the United States Department of Defense has recently established the 2012 Tuberous Sclerosis Complex Clinical Trial Award Program in an attempt to financially support the studies regarding the promotion innovative research focused on decreasing the clinical impact of tuberous sclerosis complex (TSC).

---

Core Clinical Centers for the Cardiothoracic Surgical Trials Network Program
In keeping with this mission, the National Institutes of Health has partnered with the Canadian Institutes of Health Research (CIHR), the National Heart, Lung, and Blood Institute (NHLBI), and the Institute of Circulatory and Respiratory Health (ICRH) to establish the Core Clinical Centers for the Cardiothoracic Surgical Trials Network Program.

---